Progenity to Participate in 11th Annual Partnership Opportunities in Drug Delivery Conference
September 21, 2021 07:30 ET
|
Progenity, Inc.
SAN DIEGO, Sept. 21, 2021 (GLOBE NEWSWIRE) -- Progenity, Inc. (Nasdaq: PROG), an innovative biotechnology company, announced today that the company will participate in the 11th annual Partnership...
Progenity Announces Patent Granted by USPTO for its Preeclampsia Rule-Out Test
September 14, 2021 07:30 ET
|
Progenity, Inc.
SAN DIEGO, Sept. 14, 2021 (GLOBE NEWSWIRE) -- Progenity, Inc. (Nasdaq: PROG), an innovative biotechnology company, announced today that the United States Patent and Trademark Office (USPTO) has...
Progenity to Participate in Two Upcoming Investor Conferences
September 03, 2021 07:30 ET
|
Progenity, Inc.
SAN DIEGO, Sept. 03, 2021 (GLOBE NEWSWIRE) -- Progenity, Inc. (Nasdaq: PROG), an innovative biotechnology company, today announced that the company will participate in two upcoming virtual investor...
Progenity Announces Closing of $40 Million Underwritten Public Offering
August 24, 2021 16:05 ET
|
Progenity, Inc.
SAN DIEGO, Aug. 24, 2021 (GLOBE NEWSWIRE) -- Progenity, Inc. (“Progenity”) (Nasdaq: PROG), an innovative biotechnology company, today announced the closing of its previously announced underwritten...
Progenity Announces Pricing of $40 Million Public Offering of Common Stock and Warrants
August 19, 2021 22:20 ET
|
Progenity, Inc.
SAN DIEGO, Aug. 19, 2021 (GLOBE NEWSWIRE) -- Progenity, Inc. (“Progenity”) (Nasdaq: PROG), an innovative biotechnology company, today announced the pricing of its previously announced underwritten...
Progenity Announces Proposed Underwritten Public Offering of Common Stock and Warrants
August 19, 2021 16:05 ET
|
Progenity, Inc.
SAN DIEGO, Aug. 19, 2021 (GLOBE NEWSWIRE) -- Progenity, Inc. (“Progenity”) (Nasdaq: PROG), an innovative biotechnology company, announced today that it intends to offer and sell, subject to market...
Progenity Provides Corporate Update and Reports Second Quarter 2021 Financial Results
August 12, 2021 16:01 ET
|
Progenity, Inc.
Announced successful completion of the validation study PRO-104 for the Preecludia™ rule out test for preeclampsia and achievement of the primary endpoint of the study protocol Recently achieved...
Progenity to Report Second Quarter 2021 Financial Results and Provide Corporate Update
August 05, 2021 16:05 ET
|
Progenity, Inc.
SAN DIEGO, Aug. 05, 2021 (GLOBE NEWSWIRE) -- Progenity, Inc. (NASDAQ: PROG), an innovative biotechnology company, today announced that it will report second quarter 2021 financial results on...
Progenity Announces Successful Completion of Clinical Validation Study and Achievement of the Primary Endpoint for its Preeclampsia Rule-Out Test
July 29, 2021 07:30 ET
|
Progenity, Inc.
SAN DIEGO, July 29, 2021 (GLOBE NEWSWIRE) -- Progenity, Inc. (Nasdaq: PROG), an innovative biotechnology company, announced today successful completion of the validation study for its Preecludia™...
Progenity Announces Appointment of Surbhi Sarna to its Board of Directors
June 30, 2021 07:30 ET
|
Progenity, Inc.
SAN DIEGO, June 30, 2021 (GLOBE NEWSWIRE) -- Progenity, Inc. (Nasdaq: PROG), an innovative biotechnology company, announced the appointment of Surbhi Sarna to its board of directors effective July...